Efficacy of Intradermal Tranexamic acid versus topical 5% Magnesium ascorbyl phosphate in the treatment of melasma: A head-to-head comparison

Authors

  • Muhammad Fahim Tehsil Headquarters Hospital Takhtbhai, Mardan
  • Hina Khoso Ex trainee medical officer, department of dermatology Shaheed mohtarama Benazir Bhutto medical university, Larkana sindh
  • Jahangir Khan Registrar, Department of Dermatology, AL ADAN Hospital, Kuwait.
  • Huma Gul Department of Dermatology, Khyber Teaching Hospital Peshawar.
  • Rabeeka Bakhtiar Department of Dermatology, Medical Teaching Institution Hayatabad, Peshawar

Keywords:

Tranexamic Acid (TXA), Magnesium Ascorbyl Phosphate (MAP), Epidermal melasma, MASI score

Abstract

Background Melasma is a chronic skin hyperpigmentation disorder involving 50–70% of people worldwide, mostly women of childbearing age. Various treatment modalities are available, but no previous study has undergone a head-to-head comparison of intradermal tranexamic acid (TXA) and topical magnesium ascorbyl phosphate (MAP) to treat melasma. This study aimed to fill this research gap.   Objective To compare effectiveness of intradermal (TXA) and topical (MAP) in the treatment of melasma.   Methods A total of 128 patients were enrolled, 64 in each group. Patients were divided into groups A and B using randomization technique, and their melasma severity index score (MASI) was calculated. Patients in group A were treated with four cycles of intradermal TXA at weeks 0, 4, 8, and 12. Group B was treated with topical MAP cream once a day for 12 weeks. At the end of 12 weeks, efficacy was assessed by calculating the MASI score.   Results The mean age in the injected TXA group (A) was 39.4±7.9 years and 37.5±8.3 years in the MAP group (B). In the group-wise distribution of gender, 20.3% of males and 79.7% of females were enrolled in group A, while 17.1% of males and 82.9% of females were included in group B. Baseline MASI scores for groups A and B were 16.7±5.4 and 16.06±6.15, respectively. At the end of 12 weeks, the efficacy of injected TXA was noted as being 54.7%, while 78.1% effectiveness was noted in the MAP group (P- value=0.005).   Conclusion It has been concluded that topical MAP is better than intradermal TXA for the treatment of melisma.  

References

Ebrahimi B, Naeini FF. Topical tranexamic acid as a promising treatment for melasma. J Res Med Sci. 2014 Aug;19(8):753-7. PMID: 25422661; PMCID: PMC4235096.

Kim HJ, Moon SH, Cho SH, Lee JD, Kim HS. Efficacy and Safety of Tranexamic Acid in Melasma: A Meta-analysis and Systematic Review. Acta Derm Venereol. 2017 Jul 6;97(7):776-781. doi: 10.2340/00015555-2668. PMID: 28374042.

Kim MS, Bang SH, Kim JH, Shin HJ, Choi JH, Chang SE. Tranexamic Acid Diminishes Laser-Induced Melanogenesis. Ann Dermatol. 2015 Jun;27(3):250-6. doi: 10.5021/ad.2015.27.3.250. Epub 2015 May 29. PMID: 26082580; PMCID: PMC4466276.

Miot LD, Miot HA, Silva MG, Marques ME. Physiopathology of melasma. Ann Bras Dermatol.2009;84(6):623–35

Rivas S, Pandya AG. Treatment of melasma with topical agents, peels and lasers: an evidence-based review. Am J Clin Dermatol. 2013 Oct;14(5):359-76. doi: 10.1007/s40257-013-0038-4. PMID: 23881551.

Handel AC, Miot LD, Miot HA. Melasma: a clinical and epidemiological review. An Bras Dermatol. 2014 Sep-Oct;89(5):771-82. doi: 10.1590/abd1806-4841.20143063. PMID: 25184917; PMCID: PMC4155956.

Ho SG, Chan HH. The Asian dermatologic patient: review of common pigmentary disorders and cutaneous diseases. Am J Clin Dermatol. 2009;10(3):153-68. doi: 10.2165/00128071-200910030-00002. PMID: 19354330.

Kim SJ, Park JY, Shibata T, Fujiwara R, Kang HY. Efficacy and possible mechanisms of topical tranexamic acid in melasma. Clin Exp Dermatol. 2016 Jul;41(5):480-5. doi: 10.1111/ced.12835. Epub 2016 May 2. PMID: 27135282.

Sheth VM, Pandya AG. Melasma: a comprehensive update: part II. J Am Acad Dermatol. 2011 Oct;65(4):699-714. doi: 10.1016/j.jaad.2011.06.001. PMID: 21920242.

Kanechorn Na Ayuthaya P, Niumphradit N, Manosroi A, Nakakes A. Topical 5% tranexamic acid for the treatment of melasma in Asians: a double-blind randomized controlled clinical trial. J Cosmet Laser Ther. 2012 Jun;14(3):150-4. doi: 10.3109/14764172.2012.685478. PMID: 22506692.

Rajaratnam R, Halpern J, Salim A, Emmett C. Interventions for melasma. Cochrane Database Syst Rev. 2010 Jul 7;(7):CD003583. doi: 10.1002/14651858.CD003583.pub2. PMID: 20614435.

Sarkar R, Puri P, Jain RK, Singh A, Desai A. Melasma in men: a clinical, aetiological and histological study. J Eur Acad Dermatol Venereol. 2010 Jul;24(7):768-72. doi: 10.1111/j.1468-3083.2009.03524.x. Epub 2009 Dec 15. PMID: 20015053.

Hong JW, Lee S, Kim DC, Kim KH, Song KH. Prognostic and clinicopathologic associations of BRAF mutation in primary acral lentiginous melanoma in Korean patients: a preliminary study. Ann of Dermatol. 2014 Apr 1;26(2):195-202.

Sharma R, Mahajan VK, Mehta KS, Chauhan PS, Rawat R, Shiny TN. Therapeutic efficacy and safety of oral tranexamic acid and that of tranexamic acid local infiltration with microinjections in patients with melasma: a comparative study. Clin Exp Dermatol. 2017 Oct;42(7):728-734. doi: 10.1111/ced.13164. Epub 2017 Jun 25. PMID: 28649780.

Murtaza F, Bangash AR, Khushdil A, Noor SM. Efficacy of Trichloro-Acetic Acid Peel Alone Versus Combined Topical Magnesium Ascorbyl Phosphate for Epidermal Melasma. J Coll Physicians Surg Pak. 2016 Jul;26(7):557-61. PMID: 27504543.

Perveen S, Rubin A, Berger L, Xiong W, Waqas N, Sharif S, Rao B. A Randomized Trial of Oral Tranexamic Acid With Fluocinolone-Based Triple Cream Versus Fluocinolone Based Triple Cream Alone for the Treatment of Melasma. J Drugs Dermatol. 2022 Mar 1;21(3):321-322. doi: 10.36849/JDD.6099. PMID: 35254752.

Lee JH, Park JG, Lim SH, Kim JY, Ahn KY, Kim MY, Park YM. Localized intradermal microinjection of tranexamic acid for treatment of melasma in Asian patients: a preliminary clinical trial. Dermatol Surg. 2006 May;32(5):626-31. doi: 10.1111/j.1524-4725.2006.32133.x. PMID: 16706756.

Miao F, Su MY, Jiang S, Luo LF, Shi Y, Lei TC. Intramelanocytic Acidification Plays a Role in the Antimelanogenic and Antioxidative Properties of Vitamin C and Its Derivatives. Oxid Med Cell Longev. 2019 May 12;2019:2084805. doi: 10.1155/2019/2084805. PMID: 31214276; PMCID: PMC6535878.

Pandya AG, Hynan LS, Bhore R, Riley FC, Guevara IL, Grimes P, Nordlund JJ, Rendon M, Taylor S, Gottschalk RW, Agim NG, Ortonne JP. Reliability assessment and validation of the Melasma Area and Severity Index (MASI) and a new modified MASI scoring method. J Am Acad Dermatol. 2011 Jan;64(1):78-83, 83.e1-2. doi: 10.1016/j.jaad.2009.10.051. Epub 2010 Apr 15. PMID: 20398960.

Achar A, Rathi SK. Melasma: a clinico-epidemiological study of 312 cases. Indian J Dermatol. 2011 Jul;56(4):380-2. doi: 10.4103/0019-5154.84722. PMID: 21965843; PMCID: PMC3178998.

Chung JY, Lee JH, Lee JH. Topical tranexamic acid as an adjuvant treatment in melasma: Side-by-side comparison clinical study. J Dermatolog Treat. 2016 Aug;27(4):373-7. doi: 10.3109/09546634.2015.1115812. Epub 2015 Dec 4. PMID: 26526300.

Bagherani N, Smoller BR. Efficacy of topical tranexmic acid in the treatment of melasma. Dermatol Ther. 2016 Nov;29(6):389-390. doi: 10.1111/dth.12332. Epub 2016 Jan 22. PMID: 26799239.

Shakeeb N, Noor SM, Ullah G, Paracha MM. Efficacy of Intense Pulse Light Therapy and Tripple Combination Cream Versus Intense Pulse Light Therapy and Tripple Combination Cream Alone in Epidermal Melasma Treatment. J Coll Physicians Surg Pak. 2018 Jan;28(1):13-16. doi: 10.29271/jcpsp.2018.01.13. PMID: 29290184.

Soliman MM, Ramadan SA, Bassiouny DA, Abdelmalek M. Combined trichloroacetic acid peel and topical ascorbic acid versus trichloroacetic acid peel alone in the treatment of melasma: a comparative study. J Cosmet Dermatol. 2007 Jun;6(2):89-94. doi: 10.1111/j.1473-2165.2007.00302.x. PMID: 17524124.

Batra, J., Brar, B. K., Kumar, S., & Arora, H. (2022). Tranexamic acid in melasma: Comparative evaluation of therapeutic efficacy of oral tranexamic acid versus its transepidermal administration. J Cutan Aesthet Surg, 15(4), 394-399. DOI: 10.4103/JCAS.JCAS_237_20

Dogar A, Sunil G, Sarpriya G. Comparative effeciacy of 20% trichloro-acetic acid and 50% glycolic acid peels in treatment of recalcitrant melasma. J Pak Assoc Dermatol. 2006;16(2):81-7.

Raza MH, Iftikhar N, Anwar A, Mashhood AA, Tariq S, Bin Hamid MA. Split-Face Comparative Analysis Of Micro-Needling With Tranexamic Acid Vs Vitamin C Serum In Melasma. J Ayub Med Coll Abbottabad. 2022 Jan-Mar;34(1):169-172. doi: 10.55519/JAMC-01-9840. PMID: 35466647.

Tahoun AI, Mostafa WZ, Amer MA. Dermoscopic evaluation of tranexamic acid versus Vitamin C, with microneedling in the treatment of melasma: a comparative, split-face, single-blinded study. J Dermatolog Treat. 2022 May;33(3):1623-1629. doi: 10.1080/09546634.2021.1871582. Epub 2021 Jan 12. PMID: 33393842.

Iraji F, Nasimi M, Asilian A, Faghihi G, Mozafarpoor S, Hafezi H. Efficacy of mesotherapy with tranexamic acid and ascorbic acid with and without glutathione in treatment of melasma: A split face comparative trial. J Cosmet Dermatol. 2019 Oct;18(5):1416-1421. doi: 10.1111/jocd.12874. Epub 2019 Feb 8. PMID: 30735611.

Downloads

Published

2023-10-12

How to Cite

1.
Fahim M, Khoso H, Khan J, Gul H, Bakhtiar R. Efficacy of Intradermal Tranexamic acid versus topical 5% Magnesium ascorbyl phosphate in the treatment of melasma: A head-to-head comparison . J Pak Assoc Dermatol [Internet]. 2023Oct.12 [cited 2023Nov.28];33(4):1412-20. Available from: https://jpad.com.pk/index.php/jpad/article/view/2360

Issue

Section

Original Articles